Grand Rounds Nation®

Twenty-five years ago CDC played a pivotal role in the discovery of the virus that causes hepatitis C. After the isolation of HCV, implementation of screening of blood products and organs for donation led to a decrease in rates of HCV infection between 1990 and 2009. In spite of these successes, HCV still remains a serious threat, both domestically and abroad. HCV remains the most common chronic blood borne infection in the United States, affecting approximately 3.9 million individuals. However up to 50% of HCV-infected persons are unaware of their infection. Globally, there are 180 million people who are chronically infected with the virus, and 3-4 million new infections occur every year.

Recent therapeutic advances hold the potential to halt the progression of HCV infection and disease. While HCV-infected persons can be effectively treated, more effort is needed to screen, diagnosis, treat and provide continuity of care. This session of Public Health Grand Rounds will discuss how new screening guidelines, testing methods and therapeutic advances will provide us with an opportunity to improve individual outcomes and to eventually eliminate HCV infection.

To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/

…

Tuberculosis is an ancient disease that remains an important global cause of morbidity and mortality. In most cases, TB can be treated and cured by taking a combination of several drugs for 6 to 12 months. When inappropriate or incomplete treatment takes place, however, TB bacteria can develop multidrug resistance (MDR). Annually, there are approximately 500,000 cases of MDR TB, and 150,000 deaths. Although there are simple rapid tests that have improved the diagnosis of the disease, there is immense potential to increase the number of persons diagnosed with MDR TB, and to do so more quickly to initiate treatment sooner.

This session of CDC′s Public Health Grand Rounds will explore how more patients can benefit from advances in diagnostic and treatment options, resulting in an overall reduction in morbidity from MDR TB. The role of CDC, WHO and other partners in combating this public health epidemic will also be discussed.

To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/

Tuberculosis is an ancient disease that remains an important global cause of morbidity and mortality. In most cases, TB can be treated and cured by taking a combination of several drugs for 6 to 12 months. When inappropriate or incomplete treatment takes place, however, TB bacteria can develop multidrug resistance (MDR). Annually, there are approximately 500,000 cases of MDR TB, and 150,000 deaths. Although there are simple rapid tests that have improved the diagnosis of the disease, there is immense potential to increase the number of persons diagnosed with MDR TB, and to do so more quickly to initiate treatment sooner.

This session of CDC′s Public Health Grand Rounds will explore how more patients can benefit from advances in diagnostic and treatment options, resulting in an overall reduction in morbidity from MDR TB. The role of CDC, WHO and other partners in combating this public health epidemic will also be discussed.

To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/

This session of Grand Rounds explores the burden of human papillomavirus (HPV) -associated cancer and disease in the United States and prevention through HPV vaccination. Each year, there are an estimated 26,000 HPV-attributable cancers in the United States. About 17,000 occur in women, most of which are cervical cancers, and about 9,000 occur in men, most of which are oropharyngeal cancers. CDC estimates that $8 billion are spent each year on direct medical costs for preventing and treating HPV-associated disease.

This session provides more insight about the HPV vaccination program and how CDC, state and local health departments, and health care providers are working together to achieve high vaccination levels and reduce the substantial burden of HPV-associated disease.

This is Part 3 of a lecture in three parts.

Part 1 >>

Part 2 >>

To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/

This session of Grand Rounds explores the burden of human papillomavirus (HPV) -associated cancer and disease in the United States and prevention through HPV vaccination. Each year, there are an estimated 26,000 HPV-attributable cancers in the United States. About 17,000 occur in women, most of which are cervical cancers, and about 9,000 occur in men, most of which are oropharyngeal cancers. CDC estimates that $8 billion are spent each year on direct medical costs for preventing and treating HPV-associated disease.

This session provides more insight about the HPV vaccination program and how CDC, state and local health departments, and health care providers are working together to achieve high vaccination levels and reduce the substantial burden of HPV-associated disease.

This is Part 2 of a lecture in three parts.

Part 1 >>

Part 3 >>

To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/

This session of Grand Rounds explores the burden of human papillomavirus (HPV) -associated cancer and disease in the United States and prevention through HPV vaccination. Each year, there are an estimated 26,000 HPV-attributable cancers in the United States. About 17,000 occur in women, most of which are cervical cancers, and about 9,000 occur in men, most of which are oropharyngeal cancers. CDC estimates that $8 billion are spent each year on direct medical costs for preventing and treating HPV-associated disease.

This session provides more insight about the HPV vaccination program and how CDC, state and local health departments, and health care providers are working together to achieve high vaccination levels and reduce the substantial burden of HPV-associated disease.

This is Part 1 of a lecture in three parts.

Part 2 >>

Part 3 >>

To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/

This session of Grand Rounds Nation is provided by the American College of Osteopathic Family Physicians (ACOFP), and features Dr. Robert Hasty speaking on anticoagulation therapy guidelines for nonvalvular atrial fibrillation. Topics explored in depth include first vs second line drug regimens, updates on "golden windows" for initiating therapies, and effective risk stratification methods in practice.

This session of Grand Rounds Nation is provided by the American College of Osteopathic Family Physicians (ACOFP), and features Dr. Robert Hasty speaking on anticoagulation therapy guidelines for nonvalvular atrial fibrillation. Topics explored in depth include first vs second line drug regimens, updates on "golden windows" for initiating therapies, and effective risk stratification methods in practice.

This session of Grand Rounds Nation is provided by the American College of Osteopathic Family Physicians (ACOFP), and features Dr. Robert Hasty speaking on anticoagulation therapy guidelines for nonvalvular atrial fibrillation. Topics explored in depth include first vs second line drug regimens, updates on "golden windows" for initiating therapies, and effective risk stratification methods in practice.

This session of Grand Rounds Nation is provided by the American College of Osteopathic Family Physicians (ACOFP), and features Dr. Robert Hasty speaking on anticoagulation therapy guidelines for nonvalvular atrial fibrillation. Topics explored in depth include first vs second line drug regimens, updates on "golden windows" for initiating therapies, and effective risk stratification methods in practice.